I'm LongbridgeAI, I can summarize articles.Tilray Brands (TLRY) fell 14.12% this week to close at $3.04, while the S&P 500 slipped 1.95% — leaving the stock about 12.17 percentage points behind the benchmark. The pullback was fairly orderly. Monday opened at $3.56 and marked the week high, then the stock eased through most sessions: Tuesday and Wednesday took it below $3.30 and $3.15, Thursday lifted briefly to $3.21, and Friday slipped again to close at $3.04. The weekly range of $3.56 to $3.
The Week
Tilray Brands (TLRY) fell 14.12% this week to close at $3.04, while the S&P 500 slipped 1.95% — leaving the stock about 12.17 percentage points behind the benchmark. The pullback was fairly orderly. Monday opened at $3.56 and marked the week high, then the stock eased through most sessions: Tuesday and Wednesday took it below $3.30 and $3.15, Thursday lifted briefly to $3.21, and Friday slipped again to close at $3.04. The weekly range of $3.56 to $3.03 also put Friday’s close at the bottom of the 60-session window.
Key Events
The most direct company update came on Tuesday, when Tilray Medical received INFARMED approval to perform in-house quality testing at its EU-GMP facility in Portugal. That adds a layer of operational flexibility to the firm’s European medical cannabis push. The same day, an external review warned that Tilray’s access to its revolving credit could be at risk under stricter covenant terms, raising a separate question around liquidity. The share price tracked lower across Monday to Wednesday, while regulatory news flows kept pressure on micro-cap cannabis names more broadly.
Analyst Ratings
As of Thursday, 10 institutions covered Tilray: 3 rated it buy and 7 rated it hold, with no sell or underweight ratings. The consensus rating is buy, and the consensus target sits at $5.88889, implying roughly 93.71% above the latest price. Target prices range from $4.00 to $12.00, pointing to wide dispersion among analysts. Within the pharmaceutical sector, Tilray ranks 44th out of 203 names, placing it in the lower half.
The Week Ahead
The coming week brings US housing data on Monday and Tuesday — NAHB homebuilder sentiment, housing starts and building permits — followed by EIA crude inventory releases on Wednesday. For Tilray, the key watch items remain execution around the Portugal facility and any follow-through on the credit-covenant caution flagged this week, plus broader regulatory headlines around cannabis legalisation.
In Short
This week set up a clear tension. Analyst consensus is still buy with a target well above spot, and valuation sits at a low level, but the stock logged a 14.12% weekly drop, closed at the lower end of its 60-session range, and carries a new liquidity-related warning around its revolving credit. The next thing to watch is whether the Portugal operations update can take over as the dominant narrative or whether the credit risk becomes more explicit.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.